Eraxis (anidulafungin) Injection

MAY 01, 2006

Pfizer Inc (New York, NY) has received FDA approval for the intravenous antifungal Eraxis for the treatment of candidemia, a potentially life-threatening bloodstream infection, and for the treatment of 2 other Candida infections, peritonitis and intra-abdominal abscesses. The product also is approved for the treatment of esophageal candidiasis. The recommended dose for candidemia and other Candida infections is a single 200-mg loading dose of Eraxis on day 1, followed by a 100-mg daily dose thereafter. The recommended dose for esophageal candidiasis is a single 100-mg loading dose of Eraxis on day 1, followed by a 50-mg daily dose thereafter. Eraxis is available in 50-mg single-use vials of sterile, lyophilized, preservative-free powder. The companion single-use diluent vials contain 15 mL of 20% (w/w) dehydrated alcohol in water for injection. For more information, visit www.eraxisrx.com, or call 800-438-1985.




SHARE THIS SHARE THIS
0

A Fast, Easy Way to Inform Parents About Vaccinations

Officials with the Centers for Disease Control and Prevention have prepared an informational video on this topic.

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.